International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease

[1]  E. Oger,et al.  Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab. , 2020, JAMA dermatology.

[2]  S. de Lusignan,et al.  Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study , 2020, RMD open.

[3]  D. V. van Langenberg,et al.  Editorial: direct costs are only the tip of the iceberg in inflammatory bowel disease. , 2020, Alimentary pharmacology & therapeutics.

[4]  P. Gibson,et al.  Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease , 2020, Alimentary pharmacology & therapeutics.

[5]  J. Colombel,et al.  Inflammatory Bowel Disease Therapy and Venous Thromboembolism , 2020, Current Treatment Options in Gastroenterology.

[6]  D. Rubin,et al.  Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  T. Card,et al.  Disease Activity in Inflammatory Bowel Disease Is Associated With Arterial Vascular Disease. , 2020, Inflammatory bowel diseases.

[8]  S. Bonovas,et al.  Long-term safety of approved biologics for ulcerative colitis , 2020, Expert opinion on drug safety.

[9]  A. Kaser,et al.  Crohn’s disease , 2020, Nature Reviews Disease Primers.

[10]  L. Peyrin-Biroulet,et al.  Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  S. Bonovas,et al.  Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[12]  D. Rubin,et al.  Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. , 2018, Inflammatory bowel diseases.

[13]  M. Gulati,et al.  Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease? , 2020, Trends in cardiovascular medicine.

[14]  Jason D. Wright,et al.  Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.

[16]  B. Sands,et al.  Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  K. Van Steen,et al.  Successful Infliximab Treatment is Associated With Reversal of Clotting Abnormalities in Inflammatory Bowel Disease Patients , 2019, Journal of clinical gastroenterology.

[18]  E. Haut,et al.  Cost-Benefit Limitations of Extended, Outpatient Venous Thromboembolism Prophylaxis Following Surgery for Crohn's Disease. , 2019, Diseases of the colon and rectum.

[19]  C. Sabapathy,et al.  Cost-Effectiveness of Extended Thromboprophylaxis in Patients Undergoing Colorectal Surgery from a Canadian Health Care System Perspective. , 2019, Diseases of the colon and rectum.

[20]  F. Cosentino,et al.  The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[21]  B. Sands,et al.  Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme , 2019, Alimentary pharmacology & therapeutics.

[22]  C. Lees,et al.  Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort. , 2019, Journal of Crohn's & colitis.

[23]  H. Yim,et al.  The risk of venous thromboembolism in women with inflammatory bowel disease during pregnancy and the postpartum period , 2019, Medicine.

[24]  S. Bonovas,et al.  Environmental Risk Factors for Inflammatory Bowel Diseases: an Umbrella Review of Meta-analyses. , 2019, Gastroenterology.

[25]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[26]  F. Carrat,et al.  Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study , 2019, Gut.

[27]  S. Travis,et al.  The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-Marketing Data. , 2019, Journal of Crohn's & colitis.

[28]  L. Peyrin-Biroulet,et al.  Comorbidities in inflammatory bowel disease: a call for action. , 2019, The lancet. Gastroenterology & hepatology.

[29]  D. Freedberg,et al.  Minor Hematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients with Inflammatory Bowel Disease. , 2019, Inflammatory bowel diseases.

[30]  B. Sands,et al.  Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[31]  T. Ramsay,et al.  A clinical predictive model for post‐hospitalisation venous thromboembolism in patients with inflammatory bowel disease , 2019, Alimentary pharmacology & therapeutics.

[32]  M. Weinblatt,et al.  Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study , 2019, Arthritis & rheumatology.

[33]  Zhuoli Zhang,et al.  Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials , 2019, Annals of the rheumatic diseases.

[34]  I. Elgendy,et al.  Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials , 2018, European heart journal.

[35]  S. M. Kong,et al.  P196 Risk of venous thromboembolism according to disease activity, hospitalisation, or surgry in inflammatory bowel disease: a nationwide cohort study , 2019, Journal of Crohn's and Colitis.

[36]  B. Nordestgaard,et al.  Cardiovascular Risk Profile Among Patients With Inflammatory Bowel Disease: A Population-based Study of More Than 100 000 Individuals , 2018, Journal of Crohn's & colitis.

[37]  J. Routy,et al.  Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation , 2019, Medicine.

[38]  Mary R. Kwaan,et al.  Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. , 2018, The Cochrane database of systematic reviews.

[39]  F. Dentali,et al.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. , 2018, Blood advances.

[40]  R. Collins,et al.  Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus , 2018, The New England journal of medicine.

[41]  T. Card,et al.  The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity , 2018, Alimentary pharmacology & therapeutics.

[42]  S. Steele,et al.  Extended Venous Thromboembolism Prophylaxis After Elective Surgery for IBD Patients: Nomogram-Based Risk Assessment and Prediction from Nationwide Cohort , 2018, Diseases of the colon and rectum.

[43]  Elsdon Storey,et al.  Effect of Aspirin on All‐Cause Mortality in the Healthy Elderly , 2018, The New England journal of medicine.

[44]  P. Rothwell,et al.  Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial , 2018, The Lancet.

[45]  H. Sokol,et al.  Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease , 2018, PloS one.

[46]  Hongqin Sun,et al.  Inflammatory bowel disease and cardiovascular disease incidence and mortality: A meta-analysis , 2018, European journal of preventive cardiology.

[47]  J. Wong,et al.  Incidence and Risk Factor Analysis of Thromboembolic Events in East Asian Patients With Inflammatory Bowel Disease, a Multinational Collaborative Study. , 2018, Inflammatory bowel diseases.

[48]  Siddharth Singh,et al.  Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium , 2018, The American Journal of Gastroenterology.

[49]  J. Colombel,et al.  Systematic review: safety of mesalazine in ulcerative colitis , 2018, Alimentary pharmacology & therapeutics.

[50]  P. Varjú,et al.  Steroid but not Biological Therapy Elevates the risk of Venous Thromboembolic Events in Inflammatory Bowel Disease: A Meta-Analysis , 2018, Journal of Crohn's & colitis.

[51]  W. Sandborn,et al.  Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience , 2018, Inflammatory bowel diseases.

[52]  C. Brensinger,et al.  Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease , 2018, The American Journal of Gastroenterology.

[53]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[54]  E. Finlayson,et al.  The American Society of Colon and Rectal Surgeons Clinical Practice Guideline for the Prevention of Venous Thromboembolic Disease in Colorectal Surgery. , 2018, Diseases of the colon and rectum.

[55]  J. Gagne,et al.  Comparative risk of incident venous thromboembolism in patients with inflammatory bowel disease initiating tumour necrosis factor-α inhibitors or nonbiologic agents: a cohort study , 2017, Canadian Medical Association Journal.

[56]  Guang-xia Chen,et al.  Inflammatory Bowel Disease and Risk of Ischemic Heart Disease: An Updated Meta‐Analysis of Cohort Studies , 2017, Journal of the American Heart Association.

[57]  J. Schneider,et al.  An umbrella review of meta-analyses of interventions to improve maternal outcomes for teen mothers. , 2017, Journal of adolescence.

[58]  P. Rothwell,et al.  Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study , 2017, The Lancet.

[59]  F. Carrat,et al.  Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study , 2017, Gut.

[60]  M. Cottone,et al.  Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience , 2017, Scandinavian journal of gastroenterology.

[61]  L. Peyrin-Biroulet,et al.  Ulcerative colitis , 2017, The Lancet.

[62]  Siddharth Singh,et al.  Biologic Therapy and Immunodulators are Associated with Decreased Risk of Cardiovascular Events in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis , 2017 .

[63]  R. Panaccione,et al.  The Incidence of Cardiovascular Events in Patients with Crohn’s Disease Treated with Vedolizumab and Anti-TNF Therapies , 2017 .

[64]  E. Horváth-Puhó,et al.  Inflammatory bowel disease and venous thromboembolism during pregnancy and the postpartum period , 2017, Journal of thrombosis and haemostasis : JTH.

[65]  C. Griffiths,et al.  Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials , 2017, The British journal of dermatology.

[66]  P. Davlouros,et al.  Inflammatory Bowel Disease: A Potential Risk Factor for Coronary Artery Disease , 2017, Angiology.

[67]  J. Manson,et al.  association of traditional cardiovascular risk Factors With Venous thromboembolism an individual Participant Data , 2016 .

[68]  Peiying Zhang,et al.  Risk of cardiovascular disease in inflammatory bowel disease , 2016, Experimental and therapeutic medicine.

[69]  P. Rutgeerts,et al.  The safety of vedolizumab for ulcerative colitis and Crohn's disease , 2016, Gut.

[70]  T. McGinn,et al.  External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients , 2016, Thrombosis and Haemostasis.

[71]  M. Conaway,et al.  Antitumor Necrosis Factor-&agr; Therapy Is Associated With Reduced Risk of Thromboembolic Events in Hospitalized Patients With Inflammatory Bowel Disease , 2016, Journal of clinical gastroenterology.

[72]  W. Ageno,et al.  Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH , 2016, Journal of thrombosis and haemostasis : JTH.

[73]  S. Saini,et al.  Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort , 2016, PloS one.

[74]  B. Wiens,et al.  Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. , 2016, The New England journal of medicine.

[75]  H. Tilg,et al.  The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.

[76]  J. Collen,et al.  Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score. , 2016, Chest.

[77]  S. Vermeire,et al.  Thromboembolism as an important complication of inflammatory bowel disease , 2016, European journal of gastroenterology & hepatology.

[78]  Cheng-Li Lin,et al.  Inflammatory Bowel Disease Increases the Risk of Peripheral Arterial Disease , 2015, Medicine.

[79]  A. Gottlieb,et al.  Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). , 2015, Journal of drugs in dermatology : JDD.

[80]  F. Sung,et al.  Long-term risk of mesenteric ischemia in patients with inflammatory bowel disease: a 13-year nationwide cohort study in an Asian population. , 2015, American journal of surgery.

[81]  G. Veres,et al.  Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease. , 2015, World journal of gastroenterology.

[82]  A. Gasbarrini,et al.  Prevention and Treatment of Venous Thromboembolism in Patients with IBD: A Trail Still Climbing , 2015, Inflammatory bowel diseases.

[83]  Chieh-Hsi Wu,et al.  A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia , 2015, Clinical endocrinology.

[84]  K. Bessonov,et al.  Short-term Effect of Infliximab Is Reflected in the Clot Lysis Profile of Patients with Inflammatory Bowel Disease: A Prospective Study , 2015, Inflammatory bowel diseases.

[85]  P. Lakatos,et al.  Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort , 2015, Scandinavian journal of gastroenterology.

[86]  T. Bernklev,et al.  Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: results from a prospective, population-based European inception cohort , 2015, Scandinavian journal of gastroenterology.

[87]  P. Higgins,et al.  Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[88]  W. Gulliver,et al.  The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis , 2015, Annals of the rheumatic diseases.

[89]  S. Kapadia,et al.  Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease. , 2014, Inflammatory bowel diseases.

[90]  I. Kullo,et al.  Epidemiology, risk factors and management of cardiovascular diseases in IBD , 2015, Nature Reviews Gastroenterology &Hepatology.

[91]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[92]  Biykem Bozkurt,et al.  2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[93]  S. Kapadia,et al.  Conventional Risk Factors and Cardiovascular Outcomes of Patients with Inflammatory Bowel Disease with Confirmed Coronary Artery Disease , 2014, Inflammatory Bowel Diseases.

[94]  T. Bernklev,et al.  Thromboembolism in inflammatory bowel disease: results from a prospective, population-based European inception cohort , 2014, Scandinavian journal of gastroenterology.

[95]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[96]  Jingyuan Fu,et al.  Extraintestinal Manifestations and Complications in Inflammatory Bowel Disease: From Shared Genetics to Shared Biological Pathways , 2014, Inflammatory bowel diseases.

[97]  L. Dauchet,et al.  Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. , 2014, Journal of Crohn's & colitis.

[98]  G. Agnelli,et al.  A Randomized Study on 1-Week Versus 4-Week Prophylaxis for Venous Thromboembolism After Laparoscopic Surgery for Colorectal Cancer , 2014, Annals of surgery.

[99]  Siddharth Singh,et al.  Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[100]  A. Griffiths,et al.  Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. , 2014, Gastroenterology.

[101]  Elizabeth A. Scoville,et al.  Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[102]  D. Aujesky,et al.  Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism , 2013, Thrombosis and Haemostasis.

[103]  Yeong-Wook Song,et al.  Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study* , 2013, Annals of the rheumatic diseases.

[104]  E. Akl,et al.  Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[105]  C. Hollenbeak,et al.  Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care center. , 2013, Journal of Crohn's & colitis.

[106]  G. Nguyen,et al.  Predictors and safety of venous thromboembolism prophylaxis among hospitalized inflammatory bowel disease patients. , 2013, Journal of Crohn's & colitis.

[107]  H. Tilg,et al.  Clinical presentation of venous thromboembolism in inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[108]  Suraj P. Sharma,et al.  Feasibility of Venous Thromboembolism Prophylaxis During Inflammatory Bowel Disease Flares in the Outpatient Setting: A Decision Analysis , 2013, Inflammatory bowel diseases.

[109]  H. Yuhara,et al.  Meta‐analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease , 2013, Alimentary pharmacology & therapeutics.

[110]  I. Koutroubakis,et al.  Risk of Venous Thromboembolism in Patients with Inflammatory Bowel Disease , 2013, Seminars in Thrombosis & Hemostasis.

[111]  R. Erichsen,et al.  Disease Activity in Inflammatory Bowel Disease Is Associated with Increased Risk of Myocardial Infarction, Stroke and Cardiovascular Death – A Danish Nationwide Cohort Study , 2013, PloS one.

[112]  A. Mebazaa,et al.  Rivaroxaban for thromboprophylaxis in acutely ill medical patients. , 2013, The New England journal of medicine.

[113]  Zach Jenkins.  The Padua Prediction Score , 2013 .

[114]  T. Spiro,et al.  Rivaroxaban for thromboprophylaxis in acutely ill medical patients. , 2013, The New England journal of medicine.

[115]  A. Khorana,et al.  The use of weighted and scored risk assessment models for venous thromboembolism , 2012, Thrombosis and Haemostasis.

[116]  J. Wohlfahrt,et al.  Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study , 2012, Gut.

[117]  M. Siedlinski,et al.  Local inflammation is associated with aortic thrombus formation in abdominal aortic aneurysms , 2012, Thrombosis and Haemostasis.

[118]  Michael K Gould,et al.  Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[119]  Elie A Akl,et al.  Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .

[120]  D. Greenwood,et al.  Meta-analysis of Observational Studies , 2012 .

[121]  S. Goldhaber,et al.  Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. , 2011, The New England journal of medicine.

[122]  M. Zhong,et al.  Factor V Leiden and thrombosis in patients with inflammatory bowel disease (IBD): a meta-analysis. , 2011, Thrombosis research.

[123]  L. Peyrin-Biroulet,et al.  Meta‐analysis: hyperhomocysteinaemia in inflammatory bowel diseases , 2011, Alimentary pharmacology & therapeutics.

[124]  A. Turpie,et al.  Predictive and associative models to identify hospitalized medical patients at risk for VTE. , 2011, Chest.

[125]  Xiaohua Li,et al.  Factor V Leiden and inflammatory bowel disease: a systematic review and meta-analysis , 2011, Journal of Gastroenterology.

[126]  D. Vinton.  Risk of Recurrence after a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor: A Systematic Review , 2011 .

[127]  S. Laporte,et al.  Individual patient data meta‐analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients , 2011, Journal of thrombosis and haemostasis : JTH.

[128]  C. Camma',et al.  Genetic Predisposition to Thrombophilia in Inflammatory Bowel Disease , 2011, Journal of clinical gastroenterology.

[129]  E. Horváth-Puhó,et al.  Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study , 2011, Gut.

[130]  A. Turpie,et al.  Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. , 2011, Chest.

[131]  W. Brown.  Framingham Heart Study. , 2011, Journal of clinical lipidology.

[132]  P. Prandoni,et al.  A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score , 2010, Journal of thrombosis and haemostasis : JTH.

[133]  H. Tilg,et al.  Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. , 2010, Gastroenterology.

[134]  Edeltraut Garbe,et al.  Risk of ischemic stroke in patients with Crohn's disease: A population‐based nested case‐control study† , 2010, Inflammatory bowel diseases.

[135]  I. Madan,et al.  A review of grading systems for evidence-based guidelines produced by medical specialties. , 2010, Clinical medicine.

[136]  黄亚明（整理）,et al.  Canadian Association of Gastroenterology , 2010 .

[137]  S. Goldhaber.  Risk factors for venous thromboembolism. , 2010, Journal of the American College of Cardiology.

[138]  Y. Ozin,et al.  Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease , 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[139]  J. West,et al.  Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study , 2010, The Lancet.

[140]  I. Harris,et al.  A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2010 .

[141]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[142]  Valerie Beral,et al.  Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study , 2009, BMJ : British Medical Journal.

[143]  Justina J. Sam,et al.  Rising Prevalence of Venous Thromboembolism and Its Impact on Mortality Among Hospitalized Inflammatory Bowel Disease Patients , 2008, The American Journal of Gastroenterology.

[144]  Gary H Lyman,et al.  Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.

[145]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[146]  F. Schmidt.  Meta-Analysis , 2008 .

[147]  S. Xiao,et al.  Meta‐analysis: the utility and safety of heparin in the treatment of active ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[148]  N. Nikolaidis,et al.  Thrombophilic abnormalities of natural anticoagulants in patients with ulcerative colitis. , 2007, Hepato-gastroenterology.

[149]  F. Rosendaal,et al.  Mutations in Clotting Factors and Inflammatory Bowel Disease , 2007, The American Journal of Gastroenterology.

[150]  S. Danese,et al.  Inflammation and Coagulation in Inflammatory Bowel Disease: The Clot Thickens , 2007, The American Journal of Gastroenterology.

[151]  J. Manson,et al.  Prospective Study of , 2007 .

[152]  R. Goldberg,et al.  The worcester venous thromboembolism study , 2006, Journal of General Internal Medicine.

[153]  A. Gasbarrini,et al.  Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. , 2006, Gastroenterology.

[154]  R. Goldberg,et al.  The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. , 2006, Journal of general internal medicine.

[155]  T. Battaglioli,et al.  Thrombosis in Inflammatory Bowel Diseases: Role of Inherited Thrombophilia , 2005, The American Journal of Gastroenterology.

[156]  B. Oldenburg,et al.  Risk Factors for Thromboembolic Complications in Inflammatory Bowel Disease: The Role of Hyperhomocysteinaemia , 2005, Digestive Diseases and Sciences.

[157]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.

[158]  Jing Ma,et al.  Inflammatory markers and the risk of coronary heart disease in men and women. , 2004, The New England journal of medicine.

[159]  C. Yurdaydın,et al.  Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease. , 2004, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[160]  T. MacDonald,et al.  Taking Glucocorticoids by Prescription Is Associated with Subsequent Cardiovascular Disease , 2004, Annals of Internal Medicine.

[161]  S. Yusuf,et al.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study , 2004, The Lancet.

[162]  M. Macey,et al.  Formation of Platelet-leukocyte Aggregates in Inflammatory Bowel Disease , 2004, Inflammatory bowel diseases.

[163]  Paul M. Ridker,et al.  Inflammation as a Cardiovascular Risk Factor , 2004, Circulation.

[164]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[165]  P. Deedwania.  Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? , 2003, Circulation.

[166]  S. Saibeni,et al.  Reduced Free Protein S Levels in Patients with Inflammatory Bowel Disease , 2001, Digestive Diseases and Sciences.

[167]  W. Petritsch,et al.  Anti-Cardiolipin Antibodies in Patients with Inflammatory Bowel Disease , 1999, Digestive Diseases and Sciences.

[168]  E. Kouroumalis,et al.  Anti-cardiolipin and Anti-β2-glycoprotein I Antibodies in Patients with Inflammatory Bowel Disease , 1998, Digestive Diseases and Sciences.

[169]  S. Hansen,et al.  Lack of effect of 5-aminosalicylic acid on platelet aggregation and fibrinolytic activity in vivo and in vitro , 2004, European Journal of Clinical Pharmacology.

[170]  F. Magro,et al.  High prevalence of combined thrombophilic abnormalities in patients with inflammatory bowel disease , 2003, European journal of gastroenterology & hepatology.

[171]  Shah Ebrahim,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .

[172]  A. Gasbarrini,et al.  Review Article: Inherited Thrombophilia in Inflammatory Bowel Disease , 2003, American Journal of Gastroenterology.

[173]  J. Heit,et al.  Risk factors for venous thromboembolism. , 2003, Clinics in chest medicine.

[174]  A. Jaffe,et al.  Reduction of infarct size in patients with inferior infarction with intravenous glyceryl trinitrate. A randomised study. , 1983, British heart journal.

[175]  R. Ware,et al.  Prevalence of Factor V G1691A (Leiden), Prothrombin G20210A, and Methylene Tetrahydrofolate Reductase C677T Thrombophilic Mutations in Children With Inflammatory Bowel Disease , 2002, Journal of pediatric gastroenterology and nutrition.

[176]  H. Blom,et al.  Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. , 2002, Rheumatology.

[177]  J. Douketis,et al.  Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair , 2002 .

[178]  J. Małyszko,et al.  Effects of immunosuppressive drugs on platelet aggregation in vitro. , 2002, Annals of transplantation.

[179]  É. Lerebours,et al.  Prothrombotic inherited abnormalities other than factor v leiden mutation do not play a role in venous thrombosis in inflammatory bowel disease , 2001, American Journal of Gastroenterology.

[180]  A. Gasbarrini,et al.  Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease , 2001, American Journal of Gastroenterology.

[181]  C. Bernstein,et al.  The Incidence of Deep Venous Thrombosis and Pulmonary Embolism among Patients with Inflammatory Bowel Disease: A Population-based Cohort Study , 2001, Thrombosis and Haemostasis.

[182]  M. Macey,et al.  Inhibition of platelet activation by 5‐aminosalicylic acid in inflammatory bowel disease , 2000, Alimentary pharmacology & therapeutics.

[183]  A. Gasbarrini,et al.  Inherited thrombophilia in inflammatory bowel disease , 2000 .

[184]  E. Kouroumalis,et al.  Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease , 2000, American Journal of Gastroenterology.

[185]  H. Blom,et al.  Hyperhomocysteinemia and Venous Thrombosis: A Meta-analysis , 1998, Thrombosis and Haemostasis.

[186]  P. Aldhous.  The clot thickens , 1991, Nature.

[187]  H. Brachinger,et al.  Decision analysis , 1997 .

[188]  D. Hay,et al.  Call for action. , 1971, Nursing mirror and midwives journal.

[189]  I. Leodolter.  [Crohn's disease]. , 1967, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.

[190]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.

[191]  G. A. Moore,et al.  randomised double blind placebo controlled trial , 2022 .